The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting: Results from a randomized, double‐blind, placebo‐controlled trial in Latin America
Abstract
BACKGROUND: Aprepitant is a novel neurokinin 1 (NK 1) antagonist that has been shown to improve control of chemotherapy‐induced nausea and vomiting (CINV) when added to a standard antiemetic regimen of a 5‐hydroxytriptamine‐3 antagonist plus a corticosteroid. The authors sought to evaluate further the efficacy and tolerability of aprepitant plus standard therapy in a large clinical trial. METHODS: This was a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐groups, Phase III study. Patients with cancer who were scheduled to receive treatment with high‐dose cisplatin chemotherapy were randomized to receive 1 of 2 treatment regimens; the standard therapy group received intravenous ondansetron 32 mg and oral dexamethasone 20 mg on Day 1, and oral dexamethasone 8 mg twice daily on Days 2–4. The aprepitant group received oral aprepitant 125 mg, intravenous ondansetron 32 mg, and oral dexamethasone 12 mg on Day 1; oral aprepitant 80 mg and oral dexamethasone 8 mg once daily on Days 2–3; and oral dexamethasone 8 mg on Day 4. Patients recorded episodes of emesis, use of rescue therapy, and severity of nausea in a diary. A modified intent‐to‐treat approach was used to analyze the efficacy data. The primary endpoint was complete response (no emesis and no rescue therapy) during the 5‐day period postcisplatin. Treatment comparisons were made using logistic regression models, and reported adverse events and physical and laboratory assessments were used to assess tolerability. RESULTS: A total of 523 patients were evaluated for efficacy, and 568 patients were evaluated for safety. During the 5 days after chemotherapy, the percentages of patients who achieved a complete response were 62.7% in the aprepitant group (163 of 260 patients) versus 43.3% in the standard therapy group (114 of 263 patients; P < 0.001). For Day 1, the complete response rates were 82.8% for the aprepitant group and 68.4% for the standard therapy group (P < 0.001); for Days 2–5, the complete response rates were 67.7% in the aprepitant group and 46.8% in the standard therapy group (P < 0.001). The overall incidence of adverse events was similar between the 2 treatment groups (72.8% in the aprepitant group [206 of 283 patients] and 72.6% in the standard therapy group [207 of 285 patients]) as were rates of serious adverse events, discontinuations due to adverse events, and deaths. CONCLUSIONS: In patients with cancer who are receiving high‐dose cisplatin‐based chemotherapy, therapy consisting of aprepitant (125 mg on Day 1 and 80 mg on Days 2–3) plus a standard regimen of ondansetron and dexamethasone provided superior antiemetic protection compared with standard therapy alone and was generally well tolerated. Cancer 2003;97:3090–8. © 2003 American Cancer Society. DOI 10.1002/cncr.11433
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Hesketh, P. J., Kris, M. G., Grunberg, S. M., Beck, T., Hainsworth, J. D., Harker, G., Aapro, M. S., Gandara, D., & Lindley, C. M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.103 · Cited by 605
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
de Boer-Dennert, M., de Wit, R., Schmitz, P., Djontono, J., v Beurden, V, Stoter, G., & Verweij, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.507 · Cited by 378
Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
Navari, R. M., Reinhardt, R. R., Gralla, R. J., Kris, M. G., Hesketh, P. J., Khojasteh, A., Kindler, H., Grote, T. H., Pendergrass, K., Grunberg, S. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400304 · Cited by 370
Self-citationQuality of life consequences of chemotherapy-induced emesis
Lindley, C. M., Hirsch, J. D., O'Neill, C. V., Transau, M. C., Gilbert, C. S., & Osterhaus, J. T. (1992) · Quality of Life Research · doi:10.1007/bf00434947 · Cited by 257
Campos, D., Pereira, J. R., Reinhardt, R. R., Carracedo, C., Poli, S., Vogel, C., Martinez-Cedillo, J., Erazo, A., Wittreich, J., Eriksson, L.-O., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1759 · Cited by 219
Self-citationChawla, S. P., Grunberg, S. M., Gralla, R. J., Hesketh, P. J., Rittenberg, C., Elmer, M. E., Schmidt, C., Taylor, A., Carides, A. D., Evans, J. K., et al. (2003) · Cancer · doi:10.1002/cncr.11320 · Cited by 217
Self-citationPotential of Substance P Antagonists as Antiemetics
Diemunsch, P., & Gr??lot, L. (2000) · Drugs · doi:10.2165/00003495-200060030-00002 · Cited by 188
(1998) · Annals of Oncology · doi:10.1023/a:1008471812316 · Cited by 185
Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets
Bountra, C., Bunce, K. T., Dale, T. J., Gardner, C., JORDAN, C. C., Twissell, D. J., & Ward, P. R. B. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90673-6 · Cited by 156
Belle, S. V., Lichinitser, M., Navari, R. M., Garin, A. M., Decramer, M., Riviere, A., Thant, M. M., Brestan, E., Bui, B., Eldridge, K., et al. (2002) · Cancer · doi:10.1002/cncr.10516 · Cited by 145
Self-citationCocquyt, V. F. J., Belle, S. V., Reinhardt, R., Decramer, M., O'Brien, M. E. R., Schellens, J. H. M., Borms, M., Verbeke, L., Aelst, F. V., Smet, M. D., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00416-0 · Cited by 144
Self-citationTattersall, F. D., Rycroft, W., Cumberbatch, M. J., Mason, G. S., Tye, S. J., Williamson, D. J., Hale, J. J., Mills, S. G., Finke, P. E., MacCoss, M., et al. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(99)00172-0 · Cited by 136
The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret
Tattersall, F. D., Rycroft, W., Hargreaves, R. J., et al. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90649-3 · Cited by 108
Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe
Majumdar, A. K., McCrea, J. B., Panebianco, D. L., Hesney, M., Dru, J., Constanzer, M. L., Goldberg, M. R., Murphy, G. M., Gottesdiener, K. M., Lines, C. R., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00123-1 · Cited by 108
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects
Blum, R. A., Majumdar, A. K., McCrea, J. B., Busillo, J. M., Orlowski, L. H., Panebianco, D. L., Hesney, M., Petty, K. J., Goldberg, M. R., Murphy, M. G., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80128-5 · Cited by 87
The Changeable Nature of Patients' Fears Regarding Chemotherapy
Passik, S. D., Kirsh, K. L., Rosenfeld, B. D., McDonald, M. V., & Theobald, D. (2001) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00249-9 · Cited by 73
Cited by
Chemotherapy-Induced Nausea and Vomiting
Hesketh, P. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706547 · Cited by 827
Hesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., de Wit, R., Chawla, S. P., Carides, A. D., Ianus, J., Elmer, M. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.095 · Cited by 779
Self-citationAmerican Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9591 · Cited by 740
Roila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq194 · Cited by 680
Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C., & Bunnett, N. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00031.2013 · Cited by 628
Metadata
- Authors
- Poli‐Bigelli, S., Rodrigues‐Pereira, J., Carides, A. D., Julie Ma, G., Eldridge, K., Hipple, A., Evans, J. K., Horgan, K. J., Lawson, F., & On behalf of the Aprepitant Protocol 054 Study Group
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-05-29
- Volume
- 97
- Issue
- 12
- Pages
- 3090-3098
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1994776603
- Cited by
- 564
- References
- 18
- FWCI
- 31.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.